参考文献/References:
[1] Ott A, Stolk RP, van Harskamp F,et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study[J].Neurology,1999,53(9):1937-1942.
[2] McIntyre RS, Powell AM, Kaidanovich-Beilin O,et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individualswith mood disorders[J].Behav Brain Res,2013,237:164-171. DOI: 10.1016/j.bbr.2012.09.021.
[3] Ling X, Martins RN, Racchi M,et al. Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor[J].J Alzheimers Dis,2002,4(5):369-374.
[4] Plastino M, Fava A, Pirritano D,et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2[J].J Neurol Sci,2010,288(1-2):112-116.DOI: 10.1016/j.jns.2009.09.022.
[5] Gispen WH, Biessels GJ.Cognition and synaptic plasticity in diabetes mellitus[J]. Trends Neurosci, 2000,23:542-549.
[6] Dukic-Stefanovic S,Schinzel R,Riederer P,et al.AGES in brain ageing:AGE-inhibitors as neuroprotective and anti-dementia drugs [J].Biogerontology,2001,2(1):19-34.
[7] Yan SD, Roher A, Chaney M,et al. Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide[J].Biochim Biophys Acta,2000,1502(1):145-157.
[8] Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease[J].Brain Res, 2001,888: 256-262.
[9] Beeri MS,Moshier E,Schmeidler J,et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals[J].Mech Ageing Dev,2011,132(11-12):583-587. DOI: 10.1016/j.mad.2011.10.007.
[10] Fawver JN, Schall HE, Petrofes Chapa RD, et al. Amyloid-metabolite sensing: biochemical linking of glycation modification and misfolding[J]. J Alzheimer Disease,2012, 30: 63-73.DOI:10.3233/JAD-2012-112114.
[11] Holst JJ, Vilsb ll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings[J].Diabetes Obes Metab,2013,15(1):3-14. DOI: 10.1111/j.1463-1326.2012.01628.x.
[12] Gengler S, McClean PL, McCurtin R, et al. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice[J]. Neurobiol Aging,2012,33:265-276. DOI:10.1016/j.neurobiolaging.2010.02.014.
[13] Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted with advanced age[J].Diabetes,2009,58(6):1365-1372. DOI: 10.2337/db08-1198.
[14] Gejl M, Egefjord L, Lerche S, et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase andchanging glucose clearance during hyperglycemia[J].J Cereb Blood Flow Metab,2012,32(12):2146-2152. DOI: 10.1038/jcbfm.2012.118.
[15] Shankar GM, Bloodgood BL, Townsend M, et al.Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss bymodulating an NMDA-type glutamate receptor-dependent signaling pathway[J].J Neurosci,2007,27(11):2866-2875.
[16] Li Y, Duffy KB, Ottinger MA,et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity incellular and animal models of Alzheimer's disease[J].J Alzheimers Dis,2010,19(4):1205-1219. DOI: 10.3233/JAD-2010-1314.
[17] Gault VA,Hölscher C.GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid[J].Eur J Pharmacol,2008,587(1-3):112-117.DOI: 10.1016/j.ejphar.2008.03.025.
[18] Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration[J].Vitam Horm,2010,84:331-354.DOI: 10.1016/B978-0-12-381517-0.00013-8.
[19] Puddu A,Mach F,Nencioni A,et al. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes[J].Mediators Inflamm,2013,2013:591056. DOI: 10.1155/2013/591056.
[20] Ojima A,Ishibashi Y,Matsui T,et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in thekidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J].Am J Pathol,2013,182(1):132-141. DOI: 10.1016/j.ajpath.2012.09.016.
[21] Chen S, Liu AR, An FM,et al. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4[J].Age(Dordr),2012,34(5):1211-1224.
[22] Liu J, Yin F, Zheng X,et al. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage viaMAP kinase pathway[J].Neurochem Int,2007,51(6-7):361-369.
[23] Ma T, Du X, Pick JE,et al. Glucagon-like peptide-1 cleavage product GLP-1(9-36)amide rescues synaptic plasticity andmemory deficits in Alzheimer's disease model mice[J].J Neurosci,2012,32(40):13701-13708. DOI: 10.1523/JNEUROSCI.2107-12.2012.
[24] Hölscher C, Li L. New roles for insulin-like hormones in neuronal signaling and protection: new hopes for noveltreatments of Alzheimer's disease [J].Neurobiol Aging,2010,31(9):1495-1502.DOI: 10.1016/j.neurobiolaging.2008.08.023.
[25] Abbas T, Faivre E, Hölscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interactionbetween type 2 diabetes and Alzheimer's disease[J].Behav Brain Res,2009,205(1):265-271. DOI: 10.1016/j.bbr.2009.06.035.
[26] During MJ, Cao L, Zuzga DS,et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection[J].Nat Med,2003,9(9):1173-1179.
[27] Meloni AR, DeYoung MB,Lowe C,et al. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucosedependence[J].Diabetes Obes Metab,2013,15(1):15-27. DOI: 10.1111/j.1463-1326.2012.01663.x.
[28] Gilman CP, Perry T, Furukawa K,et al. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization inhippocampal neurons[J].J Neurochem,2003,87(5):1137-1144.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(01):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(01):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[6]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(01):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[7]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[8]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(01):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[9]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(01):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[10]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(01):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[11]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(01):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[12]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(01):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[13]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(01):645.[doi:10.3760/cma.j.cn121383-20200924-09046]